1 / 9

Daclatasvir + Sofosbuvir + RBV in GT3 with Advanced Liver Disease ALLY-3+ Study

Phase 3. Treatment - Naïve and Treatment-Experienced. Daclatasvir + Sofosbuvir + RBV in GT3 with Advanced Liver Disease ALLY-3+ Study. Leroy V, et al . Hepatology 2016;63:1430-41. Daclatasvir + Sofosbuvir + RBV for HCV GT 3 Advanced Liver Disease ALLY-3+ Trial: Study Features.

aliciaj
Download Presentation

Daclatasvir + Sofosbuvir + RBV in GT3 with Advanced Liver Disease ALLY-3+ Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 Treatment-Naïve and Treatment-Experienced Daclatasvir + Sofosbuvir + RBV in GT3with Advanced Liver DiseaseALLY-3+ Study Leroy V, et al. Hepatology 2016;63:1430-41.

  2. Daclatasvir + Sofosbuvir + RBV for HCVGT 3 Advanced Liver DiseaseALLY-3+ Trial: Study Features Source: Leroy V, et al. Hepatology 2016;63:1430-41.

  3. Daclatasvir + Sofosbuvir + RBV for HCV GT 3 Advanced Liver DiseaseALLY-3+ Trial: Design 0 12 24 16 28 Week DCV + SOF + RBV N = 24 SVR12 DCV + SOF + RBV N = 26 SVR12 Drug DosingDaclatasvir (DCV): 60 mg once dailySofosbuvir (SOF: 400 mg once dailyRibavirin (RBV): GT1, given weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) Source: Leroy V, et al. Hepatology 2016;63:1430-41.

  4. Daclatasvir + Sofosbuvir + RBV for HCV GT 3 Advanced Liver Disease ALLY-3+ Trial: Patient Characteristics IFN=peginterferon, SOF=sofosbuvir, DCV=daclatasvir, RAVs=resistance-associated variants Source: Leroy V, et al. Hepatology 2016;63:1430-41.

  5. Daclatasvir + Sofosbuvir + RBV for HCV GT 3 Advanced Liver DiseaseALLY-3+ Trial: Results ALLY-3+: SVR12by Treatment Arm 21/24 24/26 45/50 SVR12 rates determined by intent-to-treat analysis Source: Leroy V, et al. Hepatology 2016;63:1430-41.

  6. Daclatasvir + Sofosbuvir + RBV for HCV GT 3 Advanced Liver DiseaseALLY-3+ Trial: Results ALLY-3+: SVR12 by Cirrhosis Status 73/75 32/34 11/19 9/13 31/36 26/30 6/6 15/18 14/16 8/8 16/18 12/14 14/14 SVR12 rates determined by intent-to-treat analysis Source: Leroy V, et al. Hepatology 2016;63:1430-41.

  7. Daclatasvir + Sofosbuvir + RBV for HCV GT 3 Advanced Liver Disease ALLY-3+ Trial: Safety Source: Leroy V, et al. Hepatology 2016;63:1430-41.

  8. Daclatasvir + Sofosbuvir + RBV for HCV GT 3 Advanced Liver Disease ALLY-3+ Trial: Conclusion Source: Leroy V, et al. Hepatology 2016;63:1430-41.

  9. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related